<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE collection SYSTEM "BioC.dtd">
<collection><source>PMC</source><date>20220621</date><key>pmc.key</key><document><id>9204721</id><infon key="license">CC BY-NC-ND</infon><passage><infon key="article-id_doi">10.1016/j.jdin.2022.05.006</infon><infon key="article-id_pii">S2666-3287(22)00063-3</infon><infon key="article-id_pmc">9204721</infon><infon key="article-id_pmid">35721299</infon><infon key="fpage">66</infon><infon key="kwd">crowdsourcing health policy inflammatory skin disease insurance underinsurance</infon><infon key="license">This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</infon><infon key="lpage">68</infon><infon key="name_0">surname:Goldman;given-names:Nathaniel</infon><infon key="name_1">surname:Nwankwo;given-names:Christy</infon><infon key="name_2">surname:Tran;given-names:Amity</infon><infon key="name_3">surname:Lim;given-names:Subin</infon><infon key="name_4">surname:Kim;given-names:Daniel Young</infon><infon key="name_5">surname:Charrow;given-names:Alexandra</infon><infon key="name_6">surname:LaChance;given-names:Avery H.</infon><infon key="section_type">TITLE</infon><infon key="title">Key words</infon><infon key="type">front</infon><infon key="volume">8</infon><infon key="year">2022</infon><offset>0</offset><text>Patient crowdfunding for inflammatory skin disease</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>51</offset><text>To the Editor: Inflammatory skin conditions are widely prevalent and affect patients physically, psychologically, and economically, from high treatment costs to functional damage, leading to decreased employment or the loss of work. To better understand the financial and psychosocial burdens of inflammatory skin disease, we sought to explore the use of fundraiser campaigns for these conditions on the publicly available crowdfunding website GoFundMe. Although previous research has characterized crowdfunding for individual dermatologic diseases, this study intended to compare data among common inflammatory skin conditions to determine the differences in psychologic distress, out-of-pocket costs, and social factors contributing to financial burden.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>807</offset><text>Fundraising campaigns were identified on the GoFundMe website using standard search functionality and included if the campaign was primarily raising funds for individual expenses for a person diagnosed with hidradenitis suppurativa (HS), atopic dermatitis (AD), psoriasis, or vitiligo (Supplementary Fig 1, available via Mendeley at https://data.mendeley.com/datasets/tnxx8g64mj/1). In total, 141, 173, 213, and 14 campaigns met the inclusion criteria for HS, AD, psoriasis, and vitiligo, respectively. The collected campaign variables included demographics, financial data, reported expenses, financial hardships, and educational methods for describing their condition. The variables were tabulated, and statistical analyses were performed using independent sample t tests and logistic regression.</text></passage><passage><infon key="file">gr1.jpg</infon><infon key="id">fig1</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>1607</offset><text>Number of fundraising campaigns for specified expenses by inflammatory skin disease type. Phototherapy was classified under “surgery/procedure” when administered by a clinician and under “medical device” while raising funds for an at-home phototherapy machine.</text></passage><passage><infon key="file">tbl1.xml</infon><infon key="id">tbl1</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>1876</offset><text>Demographics and characteristics of fundraisers for inflammatory skin diseases</text></passage><passage><infon key="file">tbl1.xml</infon><infon key="id">tbl1</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th&gt;Campaign demographics and characteristics&lt;/th&gt;&lt;th&gt;Hidradenitis suppurativa, n (%)&lt;/th&gt;&lt;th&gt;Atopic dermatitis, n (%)&lt;/th&gt;&lt;th&gt;Psoriasis, n (%)&lt;/th&gt;&lt;th&gt;Vitiligo, n (%)&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td&gt;Sex of patient&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Male&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;43 (30.5)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;75 (43.4)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;98 (46.0)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;8 (57.1)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Female&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;97 (68.8)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;97 (56.1)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;108 (50.7)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;4 (28.6)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Undisclosed&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;0 (0.0)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;0 (0.0)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;5 (2.3)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;2 (14.2)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Geographic region&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; United States&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;136 (96.5)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;124 (71.6)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;154 (72.3)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;9 (57.6)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Canada&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;0 (0.0)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;10 (5.8)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;9 (4.2)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;0 (0.0)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Europe&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;3 (2.1)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;26 (15.0)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;35 (16.4)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;1 (7.1)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Australia&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;2 (1.4)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;9 (5.2)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;4 (1.9)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;1 (7.1)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Educational tools&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Includes educational information about disease&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;91 (64.5)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;27 (15.7)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;34 (16.0)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;5 (38.5)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Photographs of disease&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;33 (23.4)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;120 (69.8)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;96 (45.1)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;12 (92.3)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Video of disease or treatment course&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;10 (7.1)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;12 (7.0)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;4 (1.9)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;0 (0.0)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Provides updates on treatment&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;45 (32.1)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;72 (41.9)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;60 (28.2)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;0 (0.0)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Psychologic distress&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Reference to psychologic distress&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;56 (39.7)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;41 (23.8)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;77 (36.2)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;10 (71.4)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Reference to stigma caused by the disease&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;16 (11.3)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;14 (8.1)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;30 (14.1)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;8 (57.1)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Financial hardships&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Loss of income&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;64 (45.4)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;53 (30.8)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;76 (35.7)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;2 (15.4)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Unemployed&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;41 (29.3)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;22 (12.8)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;45 (21.1)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;2 (15.4)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Need to cut back on work (if still employed)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;32 (22.9)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;24 (14.0)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;34 (16.0)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;0 (0.0)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Health insurance&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Specific mention of health insurance or health care system&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;46 (32.6)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;48 (27.7)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;59 (27.7)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;0 (0.0)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Uninsured&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;6 (4.3)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;13 (7.6)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;13 (6.1)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;0 (0.0)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Inadequate coverage of medical expenses if insured&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;39 (27.9)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;30 (17.4)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;44 (20.7)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;0 (0.0)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Campaign financial success&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Total donors&lt;/td&gt;&lt;td&gt;2360&lt;/td&gt;&lt;td&gt;7492&lt;/td&gt;&lt;td&gt;4256&lt;/td&gt;&lt;td&gt;19&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Campaigns reaching 100% of goals&lt;xref rid=&quot;tbl1fnlowast&quot; ref-type=&quot;table-fn&quot;&gt;∗&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;10 (8.3)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;25 (17.0)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;13 (7.8)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;0 (0.0)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Campaigns reaching &amp;gt;75% of goals&lt;xref rid=&quot;tbl1fnlowast&quot; ref-type=&quot;table-fn&quot;&gt;∗&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;13 (10.8)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;31 (21.1)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;30 (18.1)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;1 (12.5)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Campaigns reaching &amp;gt;50% of goals&lt;xref rid=&quot;tbl1fnlowast&quot; ref-type=&quot;table-fn&quot;&gt;∗&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;28 (23.3)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;52 (35.3)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;47 (28.3)&lt;/td&gt;&lt;td align=&quot;char&quot;&gt;1 (12.5)&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>1955</offset><text>Campaign demographics and characteristics	Hidradenitis suppurativa, n (%)	Atopic dermatitis, n (%)	Psoriasis, n (%)	Vitiligo, n (%)	 	Sex of patient					 	 Male	43 (30.5)	75 (43.4)	98 (46.0)	8 (57.1)	 	 Female	97 (68.8)	97 (56.1)	108 (50.7)	4 (28.6)	 	 Undisclosed	0 (0.0)	0 (0.0)	5 (2.3)	2 (14.2)	 	Geographic region					 	 United States	136 (96.5)	124 (71.6)	154 (72.3)	9 (57.6)	 	 Canada	0 (0.0)	10 (5.8)	9 (4.2)	0 (0.0)	 	 Europe	3 (2.1)	26 (15.0)	35 (16.4)	1 (7.1)	 	 Australia	2 (1.4)	9 (5.2)	4 (1.9)	1 (7.1)	 	Educational tools					 	 Includes educational information about disease	91 (64.5)	27 (15.7)	34 (16.0)	5 (38.5)	 	 Photographs of disease	33 (23.4)	120 (69.8)	96 (45.1)	12 (92.3)	 	 Video of disease or treatment course	10 (7.1)	12 (7.0)	4 (1.9)	0 (0.0)	 	 Provides updates on treatment	45 (32.1)	72 (41.9)	60 (28.2)	0 (0.0)	 	Psychologic distress					 	 Reference to psychologic distress	56 (39.7)	41 (23.8)	77 (36.2)	10 (71.4)	 	 Reference to stigma caused by the disease	16 (11.3)	14 (8.1)	30 (14.1)	8 (57.1)	 	Financial hardships					 	 Loss of income	64 (45.4)	53 (30.8)	76 (35.7)	2 (15.4)	 	 Unemployed	41 (29.3)	22 (12.8)	45 (21.1)	2 (15.4)	 	 Need to cut back on work (if still employed)	32 (22.9)	24 (14.0)	34 (16.0)	0 (0.0)	 	Health insurance					 	 Specific mention of health insurance or health care system	46 (32.6)	48 (27.7)	59 (27.7)	0 (0.0)	 	 Uninsured	6 (4.3)	13 (7.6)	13 (6.1)	0 (0.0)	 	 Inadequate coverage of medical expenses if insured	39 (27.9)	30 (17.4)	44 (20.7)	0 (0.0)	 	Campaign financial success					 	 Total donors	2360	7492	4256	19	 	 Campaigns reaching 100% of goals∗	10 (8.3)	25 (17.0)	13 (7.8)	0 (0.0)	 	 Campaigns reaching &gt;75% of goals∗	13 (10.8)	31 (21.1)	30 (18.1)	1 (12.5)	 	 Campaigns reaching &gt;50% of goals∗	28 (23.3)	52 (35.3)	47 (28.3)	1 (12.5)	 	</text></passage><passage><infon key="file">tbl1.xml</infon><infon key="id">tbl1</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>3790</offset><text>Determined after 6 months of campaign activity.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>3839</offset><text>Besides “unspecified,” the most frequently reported expenses for each condition were related to medications (for psoriasis, vitiligo, and AD) and surgeries or procedures (for HS) (Fig 1). Campaigns for HS and vitiligo reported educational information about their disease more commonly than campaigns for psoriasis and AD (Table I). Psychologic distress was frequently reported across the inflammatory conditions, with the highest incidence among patients with vitiligo (71.4%). Reference to stigma caused by skin diseases (eg, bullying or embarrassment) was also highest among patients with vitiligo (57.1%) compared with patients with the other conditions (odds ratio, 10.4; CI, 3.5-30.9). For all the inflammatory diseases, 5.9% of patients reported being uninsured, with 20.9% stating that their health insurance failed to adequately cover medical expenses. For campaigns active for &gt;6 months, the mean percentage of fundraising goals achieved was highest for AD (45.3%; SD, 51.1%), followed by psoriasis (31.7%; SD, 41.9%), HS (26.0%; SD, 40.4%), and vitiligo (10.3%; SD, 29.1%). After 1 year, campaigns providing treatment updates were more likely to achieve a greater percentage of their goals (P &lt; .001), as were fundraisers who included photographs of their disease (P = .03).</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>5135</offset><text>Taken together, these results suggest that underinsurance remains a significant burden for patients with inflammatory skin conditions. In particular, medication costs were the most frequently specified expense in this study. This finding is consistent with the rising out-of-pocket costs for therapeutics used for other inflammatory diseases. The fact that HS and vitiligo were more associated with direct, disease-oriented information speaks about the underrecognition of these conditions in the general public (at least compared with AD and psoriasis). Although providing updates or photographs was associated with greater fundraising success, this practice may pose ethical concerns if patients feel pressure to disclose sensitive medical or personal information. The study limitations include self-reported data, incomplete demographic information, and bias toward patients with inadequate financial support. The generalizability of psychologic burden may also be limited by the small sample size. Overall, this study sought to highlight the complex financial and psychosocial burden associated with these conditions.</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">title_1</infon><offset>6258</offset><text>Conflicts of interest</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">paragraph</infon><offset>6280</offset><text>Dr LaChance is the principal investigator for a research grant from Pfizer for a project exploring the role of the Janus kinase/signal transducers and activators of transcription pathway in cutaneous connective tissue diseases.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">title</infon><offset>6508</offset><text>References</text></passage><passage><infon key="fpage">383</infon><infon key="lpage">392</infon><infon key="name_0">surname:Nguyen;given-names:C.M.</infon><infon key="name_1">surname:Beroukhim;given-names:K.</infon><infon key="name_2">surname:Danesh;given-names:M.J.</infon><infon key="name_3">surname:Babikian;given-names:A.</infon><infon key="name_4">surname:Koo;given-names:J.</infon><infon key="name_5">surname:Leon;given-names:A.</infon><infon key="pub-id_doi">10.2147/CCID.S76088</infon><infon key="section_type">REF</infon><infon key="source">Clin Cosmet Investig Dermatol</infon><infon key="type">ref</infon><infon key="volume">9</infon><infon key="year">2016</infon><offset>6519</offset><text>The psychosocial impact of acne, vitiligo, and psoriasis: a review</text></passage><passage><infon key="fpage">S19</infon><infon key="issue">5</infon><infon key="lpage">S22</infon><infon key="name_0">surname:Gooderham;given-names:M.</infon><infon key="name_1">surname:Papp;given-names:K.</infon><infon key="pub-id_doi">10.1016/j.jaad.2015.07.054</infon><infon key="pub-id_pmid">26470609</infon><infon key="section_type">REF</infon><infon key="source">J Am Acad Dermatol</infon><infon key="type">ref</infon><infon key="volume">73</infon><infon key="year">2015</infon><offset>6586</offset><text>The psychosocial impact of hidradenitis suppurativa</text></passage><passage><infon key="fpage">1109</infon><infon key="issue">5</infon><infon key="lpage">1110</infon><infon key="name_0">surname:Desai;given-names:S.</infon><infon key="name_1">surname:Manjaly;given-names:P.</infon><infon key="name_2">surname:Lee;given-names:K.J.</infon><infon key="pub-id_doi">10.1016/j.jaad.2020.09.008</infon><infon key="pub-id_pmid">32926974</infon><infon key="section_type">REF</infon><infon key="source">J Am Acad Dermatol</infon><infon key="type">ref</infon><infon key="volume">86</infon><infon key="year">2022</infon><offset>6638</offset><text>Utilization of crowdfunding for expenses related to medical hair loss</text></passage><passage><infon key="fpage">465</infon><infon key="issue">2</infon><infon key="lpage">467</infon><infon key="name_0">surname:Zheng;given-names:D.X.</infon><infon key="name_1">surname:Mulligan;given-names:K.M.</infon><infon key="name_2">surname:Gallo Marin;given-names:B.</infon><infon key="pub-id_doi">10.1111/ced.14955</infon><infon key="pub-id_pmid">34614227</infon><infon key="section_type">REF</infon><infon key="source">Clin Exp Dermatol</infon><infon key="type">ref</infon><infon key="volume">47</infon><infon key="year">2022</infon><offset>6708</offset><text>Online crowdfunding for medical expenses related to hidradenitis suppurativa</text></passage><passage><infon key="comment">Published correction appears in Inflamm Bowel Dis. 2020;26(7):1118</infon><infon key="fpage">1</infon><infon key="issue">1</infon><infon key="lpage">10</infon><infon key="name_0">surname:Park;given-names:K.T.</infon><infon key="name_1">surname:Ehrlich;given-names:O.G.</infon><infon key="name_2">surname:Allen;given-names:J.I.</infon><infon key="pub-id_doi">10.1093/ibd/izz104</infon><infon key="pub-id_pmid">31112238</infon><infon key="section_type">REF</infon><infon key="source">Inflamm Bowel Dis</infon><infon key="type">ref</infon><infon key="volume">26</infon><infon key="year">2020</infon><offset>6785</offset><text>The cost of inflammatory bowel disease: an initiative from the Crohn’s &amp; Colitis foundation</text></passage><passage><infon key="section_type">REF</infon><infon key="type">footnote</infon><offset>6879</offset><text>Authors Goldman and Nwankwo are cofirst authors.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">footnote</infon><offset>6928</offset><text>Drs Charrow and LaChance are cosenior authors.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">footnote</infon><offset>6975</offset><text>Funding sources: None.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">footnote</infon><offset>6998</offset><text>IRB approval status: Not applicable.</text></passage></document></collection>
